Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine in Leptomeningeal Disease from Breast Cancer
NCT05809752Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in leptomeningeal disease (LMD), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 weeks. Started Aug 2023; status: active, not recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
leptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT05809752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809752.